Consistent with this report, data from a recent case study demonstrated that a patient with SM who developed the KIT mutation dup(501–503) prior to therapy had clinical improvement, with disappearance of circulating mast cells and decreased serum histamine and tryptase levels (44). Here, KIT is linked to systemic mastocytosis.